SlideServe
Télécharger Obtenir Pro
Menu
Accueil Pro
Préférences
ApparenceLight Aide et commentaires
© SlideServe · v2026

Presented By Antoni Ribas at 2014 ASCO Annual Meeting

aderes avatar
aderes
20 diapositives · 898 Views · Jul 25, 2014

Efficacy and Safety of the Anti-PD-1 <br />Monoclonal Antibody Pembrolizumab (MK-3475) in 411 Patients With Melanoma. Presented By Antoni Ribas at 2014 ASCO Annual Meeting. Disclosures. Presented By Antoni Ribas at 2014 ASCO Annual Meeting.

#presented by antoni ribas at 2014 asco annual meeting #presented by antoni ribas at 2014 asco annual meeting ppt #powerpoint #presentation
Presented By Antoni Ribas at 2014 ASCO Annual Meeting - slide 1
01 / 20Presented By Antoni Ribas at 2014 ASCO Annual Meeting
1 / 17

Télécharger la présentation

Presented By Antoni Ribas at 2014 ASCO Annual Meeting
Une image / un lien ci-dessous est fourni (tel quel) pour télécharger la présentation

Politique de téléchargement : le contenu du site vous est fourni TEL QUEL pour votre information et votre usage personnel ; il ne peut être vendu, concédé sous licence ni partagé sur d’autres sites sans l’accord de son auteur.Le contenu vous est fourni TEL QUEL, pour votre information et votre usage personnel uniquement. Téléchargez la présentation en cliquant sur ce lien. Lors du téléchargement, si vous ne parvenez pas à télécharger une présentation, l’éditeur a peut-être supprimé le fichier de son serveur.Pendant le téléchargement, si vous ne parvenez pas à obtenir une présentation, le fichier a peut-être été supprimé par l’éditeur.

F I N

Plus de contenu associé

Transcription de la présentation

  1. Efficacy and Safety of the Anti-PD-1 <br />Monoclonal Antibody Pembrolizumab (MK-3475) in 411 Patients With Melanoma Presented By Antoni Ribas at 2014 ASCO Annual Meeting

  2. Disclosures Presented By Antoni Ribas at 2014 ASCO Annual Meeting

  3. Pembrolizumab and Available Clinical Data: KEYNOTE-001 (NCT01295827) Presented By Antoni Ribas at 2014 ASCO Annual Meeting

  4. 411 Patients in Melanoma Expansion Cohorts: KEYNOTE-001 Presented By Antoni Ribas at 2014 ASCO Annual Meeting

  5. KEYNOTE-001 Eligibility Criteria Presented By Antoni Ribas at 2014 ASCO Annual Meeting

  6. KEYNOTE-001 Eligibility Criteria Presented By Antoni Ribas at 2014 ASCO Annual Meeting

  7. Baseline Characteristics (1) Presented By Antoni Ribas at 2014 ASCO Annual Meeting

  8. Baseline Characteristics (2) Presented By Antoni Ribas at 2014 ASCO Annual Meeting

  9. Summary of Exposurea and <br />Treatment-Related AEs by Prior IPI Presented By Antoni Ribas at 2014 ASCO Annual Meeting

  10. Treatment-Related AEs With Incidence >5% Presented By Antoni Ribas at 2014 ASCO Annual Meeting

  11. Immune-Mediated AEs Presented By Antoni Ribas at 2014 ASCO Annual Meeting

  12. Maximum Percent Change from Baseline in Tumor Sizea (Central Review, RECIST v1.1) Presented By Antoni Ribas at 2014 ASCO Annual Meeting

  13. Maximum Percent Change from Baseline in Tumor Sizea (Central Review, irRC) Presented By Antoni Ribas at 2014 ASCO Annual Meeting

  14. Confirmed ORR in Subgroups (Central Review, RECIST v1.1) Presented By Antoni Ribas at 2014 ASCO Annual Meeting

  15. Antitumor Activity by Prior Ipilimumab and Pembrolizumab Dose/Schedule Presented By Antoni Ribas at 2014 ASCO Annual Meeting

  16. Slide 16 Presented By Antoni Ribas at 2014 ASCO Annual Meeting

  17. Kaplan-Meier Estimate of PFS per RECIST 1.1, Independent Central Review Presented By Antoni Ribas at 2014 ASCO Annual Meeting

  18. Kaplan-Meier Estimate of Overall Survival Presented By Antoni Ribas at 2014 ASCO Annual Meeting

  19. Summary Presented By Antoni Ribas at 2014 ASCO Annual Meeting

  20. Acknowledgments Presented By Antoni Ribas at 2014 ASCO Annual Meeting